Stomach Cancer Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 – 2026

Stomach Cancer Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 – 2026

Stomach cancer is the fifth most common cancer globally regardless of gender as reported by the World Cancer Research Fund (WCRF) in 2018. There are many factors which cause stomach cancer such as unhealthy diet, smoking, obesity, alcohol, and Helicobacter pylori infection. According to the Cancer Research U.K. data of 2016, one out of three stomach cancer cases is related to Helicobacter pylori infection in the U.K. annually. Stomach cancer tests identify the stage of the cancer and the patient is treated accordingly. Targeted drug therapies are frequently used to treat stomach cancer as these drugs target the rapidly dividing cells and have less side effects. Drugs that target HER2 are under developmental studies to treat advanced stomach cancer. For instance, pertuzumab in combination with trastuzumab and chemotherapy is under phase 3 clinical trials to treat metastatic gastroesophageal junction or gastric cancer.

Market Dynamics

Increasing prevalence of stomach cancer worldwide is expected to boost the stomach cancer drugs market size. For instance, according to WCRF data of 2018, around one million cases of stomach cancer were diagnosed in 2018. Furthermore, increasing geriatric population is at a high risk of developing stomach cancer and men are more vulnerable to developing stomach cancer. For instance, according to the American Cancer Society (ACS) report in 2014, the average age of people diagnosed with stomach cancer is 68. As per the same source, six out of ten people diagnosed with stomach cancer annually are 65 or older, and stomach cancer is the fourth most common cancer in men.

However, the major challenge in the stomach cancer drugs market are the high expenses related to treatment of stomach cancer, which are not affordable to the middle to low income families in most countries. According to a data published in Oncotarget (impact journal) in 2017, the cost of stomach cancer drugs (considering Trastuzumab) can reach up to US$ 8,000 for four weeks and annually it can reach up to US$ 96,000.

Key features of the study:

  • This report provides in-depth analysis of the stomach cancer drugs market, market size (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global stomach cancer drugs market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Plc., Kuhnil Pharmaceutical Co. Ltd., Daiichi Sankyo Co. Ltd., Merck KGaA, AstraZeneca Plc, Otsuka Holdings Co. Ltd., Sanofi S.A., and F. Hoffmann-La Roche Ltd, Ono Pharmaceutical Co. Ltd., Bristol-Myers Squibb (BMS), Jiangsu HengRui Medicine Co. Ltd., Gilead Science Inc., Celgene Corporation, Taiho Pharmaceutical, Boston Biomedical Inc., and Merck & Co.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, government initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global stomach cancer drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for stomach cancer drugs market, research and consulting firms, new entrants, and financial analysts
Detailed Segmentation:
  • Global Stomach Cancer Drugs Market, By Therapy Type:
  • Kinase Inhibitors
  • Nucleoside Metabolic Inhibitors
  • Anthracyclines
  • Microtubule Inhibitors
  • VEGF Antibodies
  • HER2 Receptor Antagonists
  • Car T Cell Therapy
  • Global Stomach Cancer Drugs Market, By Application:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • Global Stomach cancer drugs Market, By Distribution Channel:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Global Stomach cancer drugs Market, By Region:
  • North America
  • By Country:
  • U.S.
  • Canada
  • By Therapy Type:
  • Kinase Inhibitors
  • Nucleoside Metabolic Inhibitors
  • Anthracyclines
  • Microtubule Inhibitors
  • VEGF Antibodies
  • HER2 Receptor Antagonists
  • Car T Cell Therapy
  • By Application:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • By End User:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Europe
  • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
  • By Therapy Type:
  • Kinase Inhibitors
  • Nucleoside Metabolic Inhibitors
  • Anthracyclines
  • Microtubule Inhibitors
  • VEGF Antibodies
  • HER2 Receptor Antagonists
  • Car T Cell Therapy
  • By Application:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • By End User:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Asia Pacific
  • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
  • By Therapy Type:
  • Kinase Inhibitors
  • Nucleoside Metabolic Inhibitors
  • Anthracyclines
  • Microtubule Inhibitors
  • VEGF Antibodies
  • HER2 Receptor Antagonists
  • Car T Cell Therapy
  • By Application:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • By End User:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Latin America
  • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • By Therapy Type:
  • Kinase Inhibitors
  • Nucleoside Metabolic Inhibitors
  • Anthracyclines
  • Microtubule Inhibitors
  • VEGF Antibodies
  • HER2 Receptor Antagonists
  • Car T Cell Therapy
  • By Application:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • By End User:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Middle East
  • By Country:
  • GCC
  • Israel
  • Rest of Middle East
  • By Therapy Type:
  • Kinase Inhibitors
  • Nucleoside Metabolic Inhibitors
  • Anthracyclines
  • Microtubule Inhibitors
  • VEGF Antibodies
  • HER2 Receptor Antagonists
  • Car T Cell Therapy
  • By Application:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • By End User:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Africa
  • By Country:
  • South Africa
  • Central Africa
  • North Africa
  • By Therapy Type:
  • Kinase Inhibitors
  • Nucleoside Metabolic Inhibitors
  • Anthracyclines
  • Microtubule Inhibitors
  • VEGF Antibodies
  • HER2 Receptor Antagonists
  • Car T Cell Therapy
  • By Application:
  • Adenocarcinomas
  • Gastrointestinal Stromal Tumors
  • Carcinoid Tumors
  • By End User:
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Company Profiles
  • Pfizer Inc.*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Eli Lilly and Company
  • GlaxoSmithKline Plc.
  • Kuhnil Pharmaceutical Co. Ltd.
  • Daiichi Sankyo Co. Ltd.
  • Merck KGaA
  • AstraZeneca Plc.
  • Otsuka Holdings Co. Ltd.
  • Sanofi S.A.
  • F. Hoffmann-La Roche Ltd.
  • Ono Pharmaceutical Co. Ltd.
  • Bristol-Myers Squibb (BMS)
  • Jiangsu HengRui Medicine Co. Ltd.
  • Gilead Science Inc.
  • Celgene Corporation
  • Taiho Pharmaceutical
  • Boston Biomedical Inc.
  • Merck & Co.
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objective and Assumption
Research Objectives
Assumptions
Abbreviations
2. Market Overview
Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Therapy Type
Market Snippet, By Application
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Market Opportunities
Impact Analysis
Market Trends
Key Developments
Distribution Channel Analysis
Pipeline Analysis
Regulatory Landscape
Reimbursement Scenario
Merger and Acquisition
Epidemiology Analysis
4. Global Stomach Cancer Drugs Market, By Therapy Type, 2018 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Kinase Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
Nucleoside Metabolic Inhibitors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
Anthracyclines
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
VEGF Antibodies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
HER2 Receptor Antagonists
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
Car T Cell Therapy Trastuzumab
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
Trastuzumab
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
5. Global Stomach Cancer Drugs Market, By Application, 2018 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Adenocarcinomas
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
Gastrointestinal Stromal Tumors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
Carcinoid Tumors
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
6. Global Stomach Cancer Drugs Market, By Distribution Channel, 2018 – 2026, (US$ Million)
Introduction
Market Share Analysis, 2018 and 2026 (%)
Y-o-Y Growth Analysis, 2017 – 2026
Segment Trends
Hospital Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
Retail Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
Online Pharmacy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2018 – 2026, (US$ Million)
7. Global Stomach Cancer Drugs Market, By Region, 2018 – 2026, (US$ Million)
Introduction
Market Share Analysis, By Region, 2018 and 2026 (%)
Y-o-Y Growth Analysis, By Region, 2017 – 2026
Regional Trends
North America
Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Application, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
U.S.
Canada
Europe
Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Application, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Application, 2018 – 2026, (US$ Million)
Market Size and Forecast, Distribution Channel, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
China
Japan
India
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Application, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
Brazil
Mexico
Argentina
Rest of Latin America
Africa
Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Application, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
North Africa
Central Africa
South Africa
Middle East
Market Size and Forecast, By Therapy Type, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Application, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Distribution Channel, 2018 – 2026, (US$ Million)
Market Size and Forecast, By Country, 2018 – 2026, (US$ Million)
GCC Countries
Israel
Rest of Middle East
8. Competitive Landscape
Company Profiles
Pfizer Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Eli Lilly and Company
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
GlaxoSmithKline Plc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Kuhnil Pharmaceutical Co. Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Daiichi Sankyo Co. Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Merck KGaA
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
AstraZeneca Plc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Otsuka Holdings Co. Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Sanofi S.A.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
F. Hoffmann-La Roche Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Ono Pharmaceutical Co. Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Bristol-Myers Squibb (BMS)
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Jiangsu HengRui Medicine Co. Ltd.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Gilead Science Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Celgene Corporation
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Taiho Pharmaceutical
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Boston Biomedical Inc.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Merck & Co.
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Analyst Views
9. Section
References
Research Methodology
About Us and Sales Contact
*Browse 24 market data tables and 17 figures on "Stomach Cancer Drugs Market” - Global forecast to 2026”

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook